News
Health Care Up as Eli Lilly Sees Progress on Obesity Pill -- Health Care Roundup
Health-care companies rose after promising data for Eli Lilly's oral version of popular anti-obesity medications. Shares of Lilly rose by more than 5% after the orforglipron drug candidate showed efficacy helping participants of a late-stage clinical trial lose weight. Shares of Danish rival Novo Nordisk slipped.
Wall Street’s major averages ended mostly lower on Friday, as market participants have been keeping an eye on the highly anticipated meeting between Donald Trump and Vladimir Putin. However, the S&P ...
The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.8% annually through 2033, ...
Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of ...
Eli Lilly (LLY) -5.81% Universal Health Services (UHS) -5.02% Here are some of the important healthcare stories from this week: Eli Lilly to acquire for Verve Therapeutics for up to $1.3B ...
Lilly encourages women to 'take health into their own hands' with new breast cancer awareness ad ...
Health-care companies rose as traders rotated back into a sector that has lagged the broad market for much of the year. Shares of Eli Lilly rose after the obesity drug maker said it was ...
Because those charges resulted from Eli Lilly’s suspect marketing and service arrangements, the lawsuit claims the practice violated the Texas Health Care Program Fraud Prevention Act and Texas ...
Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. The Big Pharma announced Thursday that its LillyDirect platform will now connect U.S. users to both in-person and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback